Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Aug 07 | 2025Novo London, Insulet, Senseonics, and MetaVia Q2 ‘25 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Aug 07 | 2025Lilly Leaves Door Open for Novo; Lilly Q2 ‘25 EarningsPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 07 | 2025Amgen and MannKind Q2 ’25 Earnings; Sava Raises $19M for Biosensor Development; MetaVia Extends Ph1 Obesity Study Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Aug 07 | 2025Novo Cleans Out Pipeline; Q2 ‘25 Earnings Update Purchase Blast
$599
Posted in: Autologous, Dual/triple agonist, GLP-1RA, Other, Topics Aug 06 | 2025Novo Sues Compounders…Again; Pfizer, Madrigal, Vertex, Corbus, and Esperion Q2 ‘25 Earnings; Innovent Receives IND clearance for Oral GLP-1RA; Vivani Data for Semaglutide Implant Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 04 | 2025Noom to Sell “Microdoses” of Wegovy; Sanofi Initiates Ph3 Tzield Study; MetaVia Partners for TA Discovery; Ypsomed Completes Sale of Diabetes Care Business Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Aug 04 | 2025Regeneron Q2 ‘25 Earnings; Medicare + Medicaid Potentially to Cover AOMs; Leqvio Label Expansion as MonotherapyPurchase Blast
$599
Posted in: Autologous, Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 01 | 2025Mounjaro SURPASS-CVOT Results; Dexcom, Sanofi, AbbVie, and Alnylam Q2 ‘25 Earnings; Novo Initiates Ph1 T1DM FGF21 Study Purchase Blast
$599
Posted in: Basal Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jul 31 | 2025Madrigal Acquires Oral GLP-1RA; Beta Bionics, Ionis, and Teva Q2 ‘25 Earnings; Tidepool/Abbott Integration Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 30 | 2025AstraZeneca, Merck, and Metsera Q2 ‘25 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 30 | 2025Novo Appoints Mike Doustdar as CEO; Lowers FY ’25 GuidancePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Jul 29 | 2025Lilly Initiates Ph2 Naperiglipron Trial; Dexcom Launches AI Meal-Tracking Feature; Trinity Announces New CGM+; Ascletis Ph2 Obesity Trial UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Insulin Delivery, Other, Topics Jul 28 | 2025Sciwind GLP-1RA Licensing Rumors; Lilly Completes Verve Acquisition; Adocia Ph3 Insulin Lispro Data Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jul 24 | 2025Roche, Viking, and BI Q2 ‘25 Earnings; Novo Discontinues Insulin Purchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Insulin Delivery, Topics Jul 23 | 2025Novo Loses Wegovy Patent Challenge; New Ph3 Icodec Trial; TIXiMED Appoints Advisors Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 23 | 2025AZ to Invest $50B for US Manufacturing; Madrigal Secures $500M Credit for Pipeline Expansion Purchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Glucose Monitoring, Other, Topics Jul 22 | 2025July CHMP Agenda; MiniMed 780G CE Mark for Expanded Indication; Dexcom Receiver Recall Purchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Jul 21 | 2025Obesity Spotlight: How will Merck Replace Keytruda Revenue?Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Jul 18 | 2025Abbott and Novartis Q2 ‘25 Earnings; Biomed Ph2 Quadruple Agonist Obesity Data; BMS/Pfizer Offers Eliquis in DTP Platform Purchase Blast
$599
Posted in: Glucose Monitoring, Other, Topics Jul 16 | 2025Lifescan Restructures Debt; Madrigal’s Rezdiffra Gains Patent in US Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
